WuXi Bio prescribes share buyback to relieve revenue pain
The pharma services provider has shocked investors with a steep downward revision of its earnings outlook, slashing its full-year revenue growth forecast to just 10% from an initial 30% and…
Recent Articles
RELATED ARTICLES
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK -
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
